Gastroparesis is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Gastroparesis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Gastroparesis compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gastroparesis overview
Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from stomach to small intestine, even though there is no blockage in the stomach or intestines. The symptoms of gastroparesis may include feeling full shortly after starting a meal, feeling full long after eating a meal, nausea, and vomiting. Diabetes is the most common known cause of gastroparesis.
For a complete picture of PTSR and LoA scores for drugs in Gastroparesis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.